Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
格式: Artigo
語言:Inglês
出版: Elsevier 2022-01-01
叢編:Cancer Treatment and Research Communications
主題:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
在線閱讀:http://www.sciencedirect.com/science/article/pii/S2468294222000132
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍